A selective angiotensin receptor antagonist , Valsartan , produced regression of <font color="red">left_2</font> <font color="red">ventricular_2</font> <font color="red">hypertrophy_2</font> <font color="red">associated_1</font> <font color="red">with_1</font> <font color="red">a_1</font> <font color="red">reduction_1</font> <font color="red">of_1</font> <font color="red">arterial_1</font> <font color="red">stiffness_1</font> <font color="red">._1</font> 
<br>
<br> We investigated whether a selective angiotensin II receptor blocker ( ARB ) would have a regressive effect on left ventricular hypertrophy ( LVH ) in <font color="red">patients_3</font> <font color="red">on_3</font> <font color="red">continuous_3</font> <font color="red">ambulatory_3</font> <font color="red">peritoneal_3</font> <font color="red">dialysis_3</font> <font color="red">(_3</font> <font color="red">CAPD_3</font> <font color="red">)_3</font> <font color="red">._3</font> In a double - blind study , <font color="red">24_6</font> <font color="red">CAPD_6</font> <font color="red">patients_6</font> <font color="red">with_6</font> <font color="red">LVH_6</font> <font color="red">[_6</font> <font color="red">left_6</font> <font color="red">ventricular_6</font> <font color="red">mass_6</font> <font color="red">index_6</font> <font color="red">(_6</font> <font color="red">LVMi_6</font> <font color="red">)_6</font> <font color="red">>_6</font> <font color="red">110_6</font> <font color="red">g_6</font> <font color="red">/_6</font> <font color="red">m2_6</font> <font color="red">for_6</font> <font color="red">women_6</font> <font color="red">and_6</font> <font color="red">LVMi_6</font> <font color="red">>_6</font> <font color="red">137_6</font> <font color="red">g_6</font> <font color="red">/_6</font> <font color="red">m2_6</font> <font color="red">for_6</font> <font color="red">men_6</font> <font color="red">]_6</font> <font color="red">were_2</font> <font color="red">randomized_2</font> <font color="red">to_1</font> <font color="red">12_1</font> <font color="red">months_1</font> <font color="red">'_1</font> <font color="red">administration_1</font> <font color="red">of_1</font> <font color="red">either_1</font> <font color="red">the_1</font> <font color="red">ARB_1</font> <font color="red">valsartan_1</font> <font color="red">(_1</font> <font color="red">n_1</font> <font color="red">=_1</font> <font color="red">14_1</font> <font color="red">)_1</font> <font color="red">or_1</font> <font color="red">a_1</font> <font color="red">placebo_1</font> <font color="red">(_1</font> <font color="red">n_1</font> <font color="red">=_1</font> <font color="red">10_1</font> <font color="red">)_1</font> <font color="red">._1</font> The target blood pressure ( BP ) was 140/90 mmHg or lower in both groups . The following parameters were measured before and at the end of the study : aortic and large - artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI ) application tonometry ] and cardiac echocardiography . Periodically recorded were body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance . Two - way analysis of variance for repeated measurements was used for statistical analysis . Systolic and diastolic BP were both reduced in patients treated with ARB . The LVMi was significantly reduced in <font color="red">patients_1</font> <font color="red">treated_1</font> <font color="red">with_1</font> <font color="red">ARB_1</font> ( to 121 + /- 4 from 145 + /- 5 ) but not in those receiving placebo ( to 137 + /- 3 from 152 + /- 3 , p < 0.05 ) . The decrease in LVMi was associated with a reduction in PWV and AI . <font color="red">In_1</font> <font color="red">CAPD_1</font> <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">LVH_1</font> <font color="red">,_1</font> ARB reduced LVMi in association with alterations in arterial hemodynamics .